132 related articles for article (PubMed ID: 29995287)
21. The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma.
Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cancer; 2005 Jun; 103(11):2338-43. PubMed ID: 15825161
[TBL] [Abstract][Full Text] [Related]
22. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Pino MS; Milella M; Gelibter A; Sperduti I; De Marco S; Nuzzo C; Bria E; Carpanese L; Ruggeri EM; Carlini P; Cognetti F
Oncology; 2009; 76(4):254-61. PubMed ID: 19246950
[TBL] [Abstract][Full Text] [Related]
23. [Chemoradiotherapy for locally recurrence after primary resection of biliary-pancreatic cancer].
Maemura K; Shinchi H; Noma H; Mataki Y; Kurahara H; Maeda S; Natsugoe S; Takao S
Gan To Kagaku Ryoho; 2009 Feb; 36(2):265-8. PubMed ID: 19223743
[TBL] [Abstract][Full Text] [Related]
24. Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer.
Ishikawa T; Kawashima H; Ohno E; Matsubara H; Sasaki Y; Achiwa K; Kanamori A; Sumi H; Hirai T; Nonogaki K; Tsuzuki T; Kuroiwa M; Hattori M; Maruta S; Hiramatsu T; Ando M; Hashimoto S; Hirooka Y
Oncology; 2019; 96(1):1-7. PubMed ID: 30368509
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer.
Oh SY; Lee GW; Kim HG; Kim TH; Kim HJ; Kang JH
Chemotherapy; 2008; 54(6):479-84. PubMed ID: 18832821
[TBL] [Abstract][Full Text] [Related]
26. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
Lee DW; Im SA; Kim YJ; Yang Y; Rhee J; Na II; Lee KH; Kim TY; Han SW; Choi IS; Oh DY; Kim JH; Kim TY; Bang YJ
Cancer Res Treat; 2017 Jul; 49(3):807-815. PubMed ID: 28111425
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 trial of oral S-1 combined with low-dose cisplatin for unresectable advanced pancreatic cancer.
Ina S; Tani M; Kawai M; Hirono S; Miyazawa M; Nishioka R; Fujita Y; Yamaue H
Anticancer Res; 2008; 28(4C):2373-7. PubMed ID: 18751421
[TBL] [Abstract][Full Text] [Related]
28. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
Sharma MR; Joshi SS; Karrison TG; Allen K; Suh G; Marsh R; Kozloff MF; Polite BN; Catenacci DVT; Kindler HL
Cancer; 2019 May; 125(10):1629-1636. PubMed ID: 30645764
[TBL] [Abstract][Full Text] [Related]
29. [S-1 monotherapy for pancreatic cancer].
Okusaka T; Ueno H; Ikeda M; Morizane C
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():207-12. PubMed ID: 16898004
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Shirai Y; Nakagawa A; Kawakami H; Uno T; Ito H; Saisho H
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):219-24. PubMed ID: 17189072
[TBL] [Abstract][Full Text] [Related]
31. Phase 2 Trial of Adjuvant Chemotherapy With S - 1 for Node-Positive Biliary Tract Cancer (N-SOG 09).
Seita K; Ebata T; Mizuno T; Maeda A; Yamaguchi R; Kurumiya Y; Sakamoto E; Hiramatsu K; Ando M; Nagino M
Ann Surg Oncol; 2020 Jul; 27(7):2348-2356. PubMed ID: 32180066
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy Improves Survival After Percutaneous Biliary Drainage in Patients With Pancreatic or Biliary Tract Cancer With Biliary Obstruction.
Niemelä J; Syrjälä H; Ohtonen P; Saarnio J; Kallio R
Anticancer Res; 2021 Jun; 41(6):2979-2984. PubMed ID: 34083288
[TBL] [Abstract][Full Text] [Related]
33. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.
Banerji U; van Doorn L; Papadatos-Pastos D; Kristeleit R; Debnam P; Tall M; Stewart A; Raynaud F; Garrett MD; Toal M; Hooftman L; De Bono JS; Verweij J; Eskens FA
Clin Cancer Res; 2012 May; 18(9):2687-94. PubMed ID: 22553374
[TBL] [Abstract][Full Text] [Related]
34. Second-line therapies in advanced biliary tract cancers.
Tella SH; Kommalapati A; Borad MJ; Mahipal A
Lancet Oncol; 2020 Jan; 21(1):e29-e41. PubMed ID: 31908303
[TBL] [Abstract][Full Text] [Related]
35. Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.
Ouaïssi M; Giger U; Sielezneff I; Pirrò N; Sastre B; Ouaissi A
J Biomed Biotechnol; 2011; 2011():315939. PubMed ID: 20981265
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).
Cashen A; Juckett M; Jumonville A; Litzow M; Flynn PJ; Eckardt J; LaPlant B; Laumann K; Erlichman C; DiPersio J
Ann Hematol; 2012 Jan; 91(1):33-8. PubMed ID: 21538061
[TBL] [Abstract][Full Text] [Related]
37. Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer during chemotherapy: a case-control study.
Abe K; Uwagawa T; Hamura R; Shirai Y; Yasuda J; Furukawa K; Shiozaki H; Onda S; Gocho T; Ikegami T
Med Oncol; 2022 Apr; 39(5):66. PubMed ID: 35478069
[TBL] [Abstract][Full Text] [Related]
38. [Ⅰ. Recent Trends in Chemotherapy followed by Surgery for Patients with Locally Advanced Biliary-Pancreatic Cancer].
Takano S; Kuboki S; Takayashiki T; Suzuki D; Sakai N; Hosokawa I; Mishima T; Konishi T; Nishino H; Nakada S; Miyazaki M; Ohtsuka M
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1054-1058. PubMed ID: 36281595
[No Abstract] [Full Text] [Related]
39. Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.
Sundar R; Custodio A; Petruckevich A; Chénard-Poirier M; Ameratunga M; Collins D; Lim J; Kaye SB; Tunariu N; Banerji U; de Bono J; Lopez J
Clin Oncol (R Coll Radiol); 2018 Mar; 30(3):185-191. PubMed ID: 29224898
[TBL] [Abstract][Full Text] [Related]
40. Advanced biliary tract cancer with complete regression after paclitaxel combined with tegretol therapy.
An X; Chen X; Zhang Y; Da M
Asian J Surg; 2024 Jun; 47(6):2643-2645. PubMed ID: 38521743
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
